Growth Hormone
IGF-1 Receptor Signaling Studies
Quantity
Ships from the United States with tracking · free shipping over $200
Certificates of analysis
Each certificate covers one production run, and reports on that batch alone. Open any of them to read the laboratory report exactly as the third-party lab issued it.
Authenticity
Scan the code on the label to pull up every published certificate for that compound — the same reports the third-party laboratory issued, batch by batch. Traceable from the laboratory that tested it to your bench.
Verify a batch →Independently tested
Purity is quantified by reverse-phase HPLC and identity confirmed by mass spectrometry, by an outside laboratory rather than in-house.
A certificate for your lot
The report that ships with your order describes the batch you received — not the product line, and not a representative sample.
COA-backed replacement
If material does not match the certificate issued for its lot, we replace it or refund it. Send us the lot number and we will trace it.
Tracked dispatch
Tracking is issued when the label is created, so the shipment is traceable from the moment it leaves us.
About this compound
C400H625N111O115S9
IGF-1 LR3 is a modified insulin-like growth factor 1 carrying a 13-residue N-terminal extension and a single substitution at position three. Both modifications reduce binding to IGF-binding proteins, which in native IGF-1 sequester the majority of circulating peptide. Research therefore examines free-fraction availability alongside conventional growth endpoints.
Full specification
How it works
The pathways IGF-1 LR3 acts on, and what each one does. Signalling described from preclinical models.
Insulin-Like Growth Factor Receptor Activation
Binds IGF-1R, the receptor governing growth and anabolic signalling. The receptor interaction is that of native IGF-1; what differs is how much of the peptide reaches it.
Extended Bioavailability
A 13-residue N-terminal extension and a substitution at position three both reduce binding to IGF-binding proteins. In native IGF-1 those proteins sequester the great majority of circulating peptide, so reducing that binding raises the free fraction substantially.
Protein Synthesis & Cell Survival
Downstream signalling runs through PI3K/Akt and MAPK, the pathways associated with protein synthesis and cell survival. These are measured in culture far more often than in whole animals.
Uses & applications
The main areas under study, and the study-reported figures behind them.
Reduced binding-protein affinity is precisely why this analogue is used in serum-free media, where binding proteins would otherwise sequester it.
Morris & Schmid 2000
Comparative potency at the IGF-1 receptor is measured against insulin, which engages the receptor far more weakly.
Voorhamme & Yandell 2006
Cultured myotubes measure protein synthesis and fibre size, the standard readout for anabolic signalling in vitro.
Rommel et al. 2001
The Akt pathway is the route from receptor to protein synthesis, and it is measured directly rather than inferred.
Schiaffino & Mammucari 2011
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Molecular structure
The verified reference values for this compound.
No 3D structure published
This compound is a long, flexible chain. Any single three-dimensional arrangement would be one of an enormous number it can adopt, so we do not show one. The sequence and the reference values beside this are the reliable description.
C400H625N111O115S9
Third-party verified
Every batch of IGF-1 LR3 is sent to an accredited independent laboratory before it ships. Here is what we screen for.
Quantifies purity and reports it on the lot certificate
Verifies the exact molecular identity
Lead, arsenic, cadmium & mercury
Bacterial endotoxin levels
No microbial contamination
Actual peptide mass per vial verified
FAQ
IGF-1 LR3 is a modified insulin-like growth factor 1 carrying a 13-residue N-terminal extension and a single substitution at position three. Both modifications reduce binding to IGF-binding proteins, which in native IGF-1 sequester the majority of circulating peptide. Research therefore examines free-fraction availability alongside conventional growth endpoints.
Published research on IGF-1 LR3 concentrates on Serum-Free Cell Culture, More Potent Than Insulin, Myotube Hypertrophy Pathways and IGF1–Akt/PKB Regulation. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes IGF-1 LR3 acting across Insulin-Like Growth Factor Receptor Activation, Extended Bioavailability and Protein Synthesis & Cell Survival, reported respectively as IGF-1R Agonism, Reduced IGFBP Binding and Anabolic Signaling. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
IGF-1 LR3 has a molecular formula of C400H625N111O115S9, an average mass of 9117.6 g/mol and the sequence 83 amino acids — human IGF-1(1-70) plus 13-residue N-terminal extension; Arg³. It is indexed under CAS 946870-92-4. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. IGF-1 LR3 is sterile acidified water or bacteriostatic water; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. IGF-1 LR3 is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed and peer-reviewed journals — not Routine Peptides claims.
For research use only
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
